Diabetes Partnering & Deal-Making
Diabetes Drug Discovery & Development
The 11th Diabetes Drug Discovery & Developmental Conference is part of GTCbio’s Diabetes Summit which encompasses the drug discovery and partnering aspects of diabetes in two separate consecutive conferences. Experts from industry and academia will discuss strategies to target Type 1 and Type 2 diabetes in presentations, and round-table discussions that highlight basic research novel therapeutic targets, translation to the clinic, and other relevant topics.
- Going Back to the Basics – Street Light Effect
- Novel Therapeutic Targets & Strategies
- Translation to The Clinic: What’s in the Pipeline
- Joint Plenary Session: Where do We Stand with Cell Therapy in Diabetes?
This conference is part of the Diabetes Summit taking place April 2018 in Boston, MA which includes two back-to-back conferences:
The 2018 Advisory Committee
|2017 Advisory Board Members|
|Robert Geho, Diasome Pharmaceuticals Inc|
|Zan Fleming, Kinexum|
|Alan Cherrington, Vanderbilt|
|Nirja Patel, ALPCO Diagnostics|
|Vivek Shenoy, Renovo|
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
The 2018 sponsorship is currently in process.
Please come back and visit this page for updates.
BELOW ARE THE SPONSORS FROM 2017.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
CrownBio’s Cardiovascular and Metabolic Disease (CVMD) portfolio is a unique continuum of translational platforms that model human diseases such as diabetes, obesity, renal disease, NAFLD/NASH etc. These translational platforms help bridge the preclinical to clinical gap and enable our clients to take strategic go/no-go decisions in drug development.
Bachem provides comprehensive services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based APIs. The group has a global reach with more experience and know-how than any other company in the industry. Bachem. Pioneering Partner for Peptides
Merck has worked for more than 150 years to discover, develop and deliver vaccines, medications and animal health products that save and improve millions of lives. Partnerships are a vital part of our strategy for bringing forward new therapies. Discover more about how we can work together at www.merck.com/licensing.